Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
0.3% Sodium Hyaluronate for Recurrent Corneal Epithelium Exfoliation
NCT03000556Phase 3Unknown
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Aili in corneal abrasion (2 arms). Primary endpoint: Incidence of Recurrent Corneal Epithelium Exfoliation at 6 months. Status: unknown.
02
Drugs
Aili
03
Conditions
corneal abrasion
Beyond the preview
Go deeper on NCT03000556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000556.